News & Updates
Filter by Specialty:
KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo
First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.
KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo
07 May 2025
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
07 May 2025
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.